The fight against Alzheimer's disease seems to be advancing, and one biotech developing a treatment for the degenerative brain disorder benefited from this on Monday.

This was Alnylam Pharmaceuticals (NASDAQ: ALNY), which saw its share price rise by nearly 3% on the day thanks to encouraging news from an early-stage clinical trial of an investigational Alzheimer's drug. By comparison, the S&P 500 index only crept 0.4% higher.

Alnylam published the interim results of a phase 1 study of its ALN-APP concurrent with a presentation made by the biotech at an Alzheimer's conference in the Netherlands. ALN-APP not only addresses Alzheimer's but also cerebral amyloid angiopathy (CAA), an affliction in which certain proteins accumulate in the arteries located in the brain. 

Continue reading

Source Fool.com